Hypothyroidism after Treatment with Interleukin-2 and Lymphokine-Activated Killer Cells
- 16 June 1988
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 318 (24) , 1557-1563
- https://doi.org/10.1056/nejm198806163182401
Abstract
The development of a goiter and hypothyroidism in a 28-year-old man in whom metastatic melanoma had been treated with interleukin-2 and lymphokine-activated killer cells (LAK cells) prompted us to assess thyroid function in patients undergoing this therapy.This publication has 38 references indexed in Scilit:
- A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 AloneNew England Journal of Medicine, 1987
- Constant-Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced CancerNew England Journal of Medicine, 1987
- Immunoregulation in Autoimmune Thyroid DiseaseNew England Journal of Medicine, 1987
- High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer. Responses, treatment-related morbidity, and histologic findingsJAMA, 1986
- Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic CancerNew England Journal of Medicine, 1985
- Induction of experimental autoimmune thyroiditis in mice with in vitro activated splenic T cellsCellular Immunology, 1985
- Epithelial cells expressing aberrant MHC class II determinants can present antigen to cloned human T cellsNature, 1984
- Immunology: Graft rejection and Ia antigens — paradox resolved?Nature, 1983
- AN IMPROVED RADIORECEPTOR ASSAY FOR TSH RECEPTOR ANTIBODIESClinical Endocrinology, 1982
- Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.The Journal of Experimental Medicine, 1982